SAT0183 Clinical remission in subjects with rheumatoid arthritis treated with subcutaneous tocilizumab as monotherapy or in combination with methotrexate or other synthetic dmards: a real-world clinical trial (tospace)

• Published in: Annals of the rheumatic diseases Vol. 76; no. Suppl 2; p. 840
• Main Authors: Sanmarti, R, Mola, E Martín, Fonseca, JE, Veale, DJ, Escudero, A, González, C
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 01.06.2017
• Subjects: Clinical trials; Drug development; Immunosuppressive agents; Intolerance; Methotrexate; Monoclonal antibodies; Patients; Remission; Rheumatoid arthritis

BackgroundSubcutaneous tocilizumab (TCZ-SC) has demonstrated non-inferiority to TCZ-IV and superiority to placeboObjectivesThe primary objective of this study was to assess the 24-week efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) 162 mg weekly (qw) as monotherapy or in combination with...